Keymed Biosciences Inc
02162
Company Profile
Business description
Keymed Biosciences Inc is a biotechnology company with multiple clinical-stage assets. The company is focused on the in-house discovery and development of biological therapies that address large underserved medical needs in the autoimmune and oncology therapeutic areas. Its clinical-stage drug candidates include CM310, CM326, CM313, and CM336 among others. The company is engaged in biopharmaceutical research and development, which is regarded as a single reportable segment. Geographically, it generates a majority of its revenue from overseas markets and the rest from Mainland China.
Contact
No. 669 Fenghuang Road
Shuangliu District
Chengdu
Sichuan610219
CHNT: +86 2888610620
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
1,625
Stocks News & Analysis
stocks
Margins have bottomed for ASX listed consumer goods company
Impact of tariffs have been priced in.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,988.30 | 61.40 | -0.68% |
| CAC 40 | 8,365.46 | 34.65 | -0.41% |
| DAX 40 | 24,952.76 | 186.93 | -0.74% |
| Dow JONES (US) | 51,758.95 | 46.24 | 0.09% |
| FTSE 100 | 10,455.87 | 18.02 | 0.17% |
| HKSE | 23,336.28 | 432.24 | -1.82% |
| NASDAQ | 25,760.44 | 406.16 | -1.55% |
| Nikkei 225 | 69,788.38 | 2,565.58 | -3.55% |
| NZX 50 Index | 13,435.77 | 10.28 | -0.08% |
| S&P 500 | 7,396.75 | 76.04 | -1.02% |
| S&P/ASX 200 | 8,787.00 | 48.10 | -0.54% |
| SSE Composite Index | 4,106.25 | 56.85 | -1.37% |